07:16 AM EDT, 09/08/2025 (MT Newswires) -- Ideaya Biosciences ( IDYA ) said Monday that interim phase 2 data for darovasertib in the neoadjuvant setting for primary uveal melanoma showed ocular tumor shrinkage, reduced radiation doses to critical eye structures, and improved vision.

The preliminary data also showed a reduced risk of long-term blindness after plaque brachytherapy, Ideaya said.

Of 39 patients enrolled in the trial, 21 were efficacy-evaluable who received three or more cycles of darovasertib and had baseline and on-treatment tumor assessment as well as dosimetry and visual acuity score data available, according to the company.

Sixteen or 76% of patients achieved at least 20% tumor shrinkage, while 48% saw a 20% or greater reduction in radiation dose to key visual structures, the company said.

Visual improvement was observed in 65% of the patients, while 67% showed "any reduction" in their risk of legal blindness at three years post-plaque brachytherapy, with 38% achieving over 20% risk reduction, the company said.

Darovasertib was generally well tolerated with a manageable safety profile, Ideaya said.